Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 700

1.

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S.

Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32163. [Epub ahead of print]

PMID:
30694523
2.

5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells.

Oing C, Verem I, Mansour WY, Bokemeyer C, Dyshlovoy S, Honecker F.

Int J Mol Sci. 2018 Dec 21;20(1). pii: E21. doi: 10.3390/ijms20010021.

3.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE.

Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7.

PMID:
30529901
4.

Apixaban for the Treatment of Chronic Disseminated Intravascular Coagulation: A Report of Two Cases.

Janjetovic S, Holstein K, Dicke C, Bokemeyer C, Langer F.

Hamostaseologie. 2018 Nov 19. doi: 10.1055/s-0038-1675386. [Epub ahead of print]

PMID:
30453340
5.

Palliative treatment of germ cell cancer.

Oing C, Giannatempo P, Honecker F, Oechsle K, Bokemeyer C, Beyer J.

Cancer Treat Rev. 2018 Dec;71:102-107. doi: 10.1016/j.ctrv.2018.10.007. Epub 2018 Oct 22. Review.

6.

Multi-omic based molecular profiling of advanced cancer identifies treatable targets and improves survival in individual patients.

Samsen A, von der Heyde S, Bokemeyer C, David KA, Flath B, Graap M, Grebenstein B, Heflik L, Hollburg W, Layer P, von Leitner E, Overkamp F, Saeger W, Schneider S, von Seydewitz CU, Stang A, Stein A, Zornig C, Juhl H.

Oncotarget. 2018 Oct 5;9(78):34794-34809. doi: 10.18632/oncotarget.26198. eCollection 2018 Oct 5.

7.

[Positron emission tomography in germ cell tumors in men : Possibilities and limitations].

Schriefer P, Hartmann M, Oechsle K, Meyer CP, Klutmann S, Fisch M, Bokemeyer C, Oing C.

Urologe A. 2018 Oct 29. doi: 10.1007/s00120-018-0797-x. [Epub ahead of print] Review. German.

PMID:
30374517
8.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.

Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I.

Support Care Cancer. 2018 Oct 20. doi: 10.1007/s00520-018-4513-6. [Epub ahead of print]

PMID:
30343410
9.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv271. doi: 10.1093/annonc/mdy323. No abstract available.

PMID:
30285221
10.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Díaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL.

Eur J Cancer. 2018 Nov;103:205-213. doi: 10.1016/j.ejca.2018.08.020. Epub 2018 Sep 27.

PMID:
30268921
11.

The Impact of Bleeding Disorders on the Socioeconomic Status of Adult Patients.

Holstein K, von Mackensen S, Bokemeyer C, Langer F.

Hamostaseologie. 2018 Aug;38(3):150-157. doi: 10.5482/HAMO-16-12-0047. Epub 2018 Sep 27.

PMID:
30261520
12.

Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.

Fenner M, Oing C, Dieing A, Gauler T, Oechsle K, Lorch A, Hentrich M, Kopp HG, Bokemeyer C, Honecker F.

J Cancer Res Clin Oncol. 2019 Mar;145(3):717-723. doi: 10.1007/s00432-018-2752-z. Epub 2018 Sep 19.

PMID:
30232558
13.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S.

J Thorac Oncol. 2018 Dec;13(12):e243-e246. doi: 10.1016/j.jtho.2018.08.2025. Epub 2018 Sep 8. No abstract available.

PMID:
30205165
14.

ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.

PMID:
30113631
15.

Der ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis.

Bokemeyer C, Busse R, Engel J, Gebauer A, Hallek M, Heinemann V, Lüftner D, Wörmann B.

Oncol Res Treat. 2018;41 Suppl 3:2-26. doi: 10.1159/000490082. Epub 2018 Jul 26. No abstract available.

16.

Vorwort.

Hallek M, Bokemeyer C, Lüftner D, Weissinger F.

Oncol Res Treat. 2018;41 Suppl 3:1. doi: 10.1159/000491683. Epub 2018 Jul 26. No abstract available.

17.

A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.

Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M.

Leuk Lymphoma. 2018 Jul 22:1-7. doi: 10.1080/10428194.2018.1482538. [Epub ahead of print]

PMID:
30033830
18.

Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer.

Oing C, Bokemeyer C.

Curr Opin Urol. 2018 Sep;28(5):479-484. doi: 10.1097/MOU.0000000000000531.

PMID:
29957683
19.

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.

Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W.

Oncogene. 2018 Sep;37(39):5269-5280. doi: 10.1038/s41388-018-0288-y. Epub 2018 May 31.

20.

Synthesis and anticancer activity of the derivatives of marine compound rhizochalin in castration resistant prostate cancer.

Dyshlovoy SA, Otte K, Tabakmakher KM, Hauschild J, Makarieva TN, Shubina LK, Fedorov SN, Bokemeyer C, Stonik VA, von Amsberg G.

Oncotarget. 2018 Mar 30;9(24):16962-16973. doi: 10.18632/oncotarget.24764. eCollection 2018 Mar 30.

21.

Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy.

Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner JM, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S.

Cancer Res. 2018 Jun 15;78(12):3220-3232. doi: 10.1158/0008-5472.CAN-17-3415. Epub 2018 Apr 19.

PMID:
29674477
22.

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.

Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M.

Oncoimmunology. 2018 Jan 15;7(4):e1417720. doi: 10.1080/2162402X.2017.1417720. eCollection 2018.

23.

Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial.

Scholl I, Hahlweg P, Lindig A, Bokemeyer C, Coym A, Hanken H, Müller V, Smeets R, Witzel I, Kriston L, Härter M.

Implement Sci. 2018 Mar 27;13(1):51. doi: 10.1186/s13012-018-0740-y.

24.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells.

Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S.

Haematologica. 2018 Jun;103(6):939-948. doi: 10.3324/haematol.2017.181354. Epub 2018 Mar 22.

25.

BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.

Oing C, Tennstedt P, Simon R, Volquardsen J, Borgmann K, Bokemeyer C, Petersen C, Dikomey E, Rothkamm K, Mansour WY.

Cancer Lett. 2018 Jun 1;423:60-70. doi: 10.1016/j.canlet.2018.03.007. Epub 2018 Mar 8.

PMID:
29526801
26.

Therapeutic approaches for refractory germ cell cancer.

Oing C, Seidel C, Bokemeyer C.

Expert Rev Anticancer Ther. 2018 Apr;18(4):389-397. doi: 10.1080/14737140.2018.1450630. Epub 2018 Mar 12. Review.

PMID:
29516750
27.

Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.

Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Bokemeyer C.

Eur J Cancer. 2018 May;94:16-25. doi: 10.1016/j.ejca.2018.01.113. Epub 2018 Mar 20.

PMID:
29505967
28.

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv96-iv110. doi: 10.1093/annonc/mdx758. No abstract available.

29.

Treatment of Metastatic Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE) - Long-Term Disease Control by Multimodal Therapy.

Quidde J, Alsdorf WH, von Amsberg G, Wilczak W, Bokemeyer C.

Oncol Res Treat. 2018;41(1-2):58-60. doi: 10.1159/000480017. Epub 2018 Jan 22. Erratum in: Oncol Res Treat. 2018;41(3):146.

30.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project.

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR; Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD).

J Natl Cancer Inst. 2018 Jun 1;110(6):638-648. doi: 10.1093/jnci/djx253.

31.

Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel.

Boormans JL, Mayor de Castro J, Marconi L, Yuan Y, Laguna Pes MP, Bokemeyer C, Nicolai N, Algaba F, Oldenburg J, Albers P.

Eur Urol. 2017 Nov 20. pii: S0302-2838(17)30826-6. doi: 10.1016/j.eururo.2017.09.025. [Epub ahead of print] Review.

PMID:
29100813
32.

Specific Characteristics of Patients with Advanced Genitourinary Cancer Receiving Specialized Inpatient Palliative Care.

Iversen K, Oechsle K, Oing C, Bokemeyer C, Seidel C.

Oncol Res Treat. 2017;40(10):609-614. doi: 10.1159/000478934. Epub 2017 Sep 19.

33.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.

Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S.

Nat Commun. 2017 Aug 16;8(1):269. doi: 10.1038/s41467-017-00327-8.

34.

The impact of bleeding disorders on the socioeconomic status of adult patients. Results of a comparative single centre cohort study.

Holstein K, von Mackensen S, Bokemeyer C, Langer F.

Hamostaseologie. 2017 Jul 10;99(99). doi: 10.5482/HAMO-16-12-0047. [Epub ahead of print]

PMID:
28692112
35.

[New Aspects in Treatment of Metastatic Prostate Cancer].

von Amsberg G, Bokemeyer C.

Dtsch Med Wochenschr. 2017 Aug;142(15):1106-1110. doi: 10.1055/s-0043-105768. Epub 2017 Jun 23. German.

PMID:
28645133
36.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M.

Haematologica. 2017 Sep;102(9):e368-e370. doi: 10.3324/haematol.2017.169235. Epub 2017 May 18. No abstract available.

37.

Testis cancer: some problems still remain unsolved.

Albers P, Bokemeyer C.

World J Urol. 2017 Aug;35(8):1159-1160. doi: 10.1007/s00345-017-2041-5. Epub 2017 May 16. No abstract available.

PMID:
28509970
38.

Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells.

Dyshlovoy SA, Rast S, Hauschild J, Otte K, Alsdorf WH, Madanchi R, Kalinin VI, Silchenko AS, Avilov SA, Dierlamm J, Honecker F, Stonik VA, Bokemeyer C, von Amsberg G.

Leuk Lymphoma. 2017 Dec;58(12):2905-2915. doi: 10.1080/10428194.2017.1317091. Epub 2017 May 16.

PMID:
28508718
39.

Quality of life, psychological burden, needs, and satisfaction during specialized inpatient palliative care in family caregivers of advanced cancer patients.

Ullrich A, Ascherfeld L, Marx G, Bokemeyer C, Bergelt C, Oechsle K.

BMC Palliat Care. 2017 May 10;16(1):31. doi: 10.1186/s12904-017-0206-z.

40.

Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension.

Harbaum L, Baaske KM, Simon M, Oqueka T, Sinning C, Glatzel A, Lüneburg N, Sydow K, Bokemeyer C, Klose H.

BMC Pulm Med. 2017 Apr 26;17(1):72. doi: 10.1186/s12890-017-0407-5.

41.

Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin.

Dyshlovoy SA, Otte K, Venz S, Hauschild J, Junker H, Makarieva TN, Balabanov S, Alsdorf WH, Madanchi R, Honecker F, Bokemeyer C, Stonik VA, von Amsberg G.

Proteomics. 2017 Jun;17(11). doi: 10.1002/pmic.201700048.

PMID:
28445005
42.

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.

Latuske EM, Stamm H, Klokow M, Vohwinkel G, Muschhammer J, Bokemeyer C, Jücker M, Kebenko M, Fiedler W, Wellbrock J.

Oncotarget. 2017 Apr 25;8(17):29187-29201. doi: 10.18632/oncotarget.16304.

43.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ; ARCAD Clinical Trials Program.

J Clin Oncol. 2017 Jun 10;35(17):1929-1937. doi: 10.1200/JCO.2016.71.5771. Epub 2017 Apr 17.

44.

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.

Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH, Berdel WE.

Acta Haematol. 2017;137(3):163-172. doi: 10.1159/000463534. Epub 2017 Apr 12.

45.

Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer.

Dulz S, Asselborn NH, Dieckmann KP, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger LA, Alsdorf W, Mankichian B, Meyer C, Vetterlein MW, Gild P, Ludwig TA, Soave A, Schriefer P, Becker A, Ahyai SA, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun FK, Kluth LA.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1319-1325. doi: 10.1007/s00432-017-2384-8. Epub 2017 Mar 9.

PMID:
28281024
46.

MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma.

Akyüz N, Albert-Konetzny N, Pott C, Callet-Bauchu E, Bokemeyer C, Murga Penas EM, Dierlamm J.

Leuk Lymphoma. 2017 Oct;58(10):2480-2484. doi: 10.1080/10428194.2017.1296144. Epub 2017 Mar 2. No abstract available.

PMID:
28278699
47.

Mutational landscape reflects the biological continuum of plasma cell dyscrasias.

Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M.

Blood Cancer J. 2017 Feb 24;7(2):e537. doi: 10.1038/bcj.2017.19.

48.

Corrigendum re: "Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours" [Eur Urol 2017;71:213-20].

Dieckmann KP, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G.

Eur Urol. 2017 May;71(5):e161. doi: 10.1016/j.eururo.2017.01.041. Epub 2017 Feb 13. No abstract available.

PMID:
28209431
49.

The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.

Dyshlovoy SA, Madanchi R, Hauschild J, Otte K, Alsdorf WH, Schumacher U, Kalinin VI, Silchenko AS, Avilov SA, Honecker F, Stonik VA, Bokemeyer C, von Amsberg G.

BMC Cancer. 2017 Feb 1;17(1):93. doi: 10.1186/s12885-017-3085-z.

50.

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.

Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K.

Support Care Cancer. 2017 Jun;25(6):1819-1828. doi: 10.1007/s00520-017-3572-4. Epub 2017 Jan 22.

Supplemental Content

Loading ...
Support Center